Reviews & Opinions
Independent and trusted. Read before buy Chicco Chicco Spring!

Chicco Chicco Spring


Bookmark
Chicco Chicco Spring

Bookmark and Share

 

Chicco Chicco SpringAbout Chicco Chicco Spring
Here you can find all about Chicco Chicco Spring like manual and other informations. For example: review.

Chicco Chicco Spring manual (user guide) is ready to download for free.

On the bottom of page users can write a review. If you own a Chicco Chicco Spring please write about it to help other people.
[ Report abuse or wrong photo | Share your Chicco Chicco Spring photo ]

 

 

Manual

Preview of first few manual pages (at low quality). Check before download. Click to enlarge.
Manual - 1 page  Manual - 2 page  Manual - 3 page 

Download (English)
Chicco Chicco Spring, size: 2.2 MB

 

Chicco Chicco Spring

 

 

Video review

Greenbelt Fashion Walk 2010 Gymboree Kids for Chicco

 

User reviews and opinions

<== Click here to post a new opinion, comment, review, etc.

No opinions have been provided. Be the first and add a new opinion/review.

 

Documents

doc0

a chandler chicco publication

ISSUE 15 Spring 2010

INSIDE THIS ISSUE:
A Letter from Bob Chandler Five Lessons from Health Reform Whats Your GQ? Gender Intelligence in Healthcare Marketing Key Trends for 2010: What They Mean to Healthcare Marketers 2010: The Year of the Patient Patient Blogger Engagement Spotlight on Germany: A Leader in the Global Healthcare Market Daiichi Sankyo & Lilly: Launching the New Oral Anti-platelet Agent Efient in Germany 12
About Chandler Chicco Companies:
handler Chicco Agency is a global pure-play healthcare public relations C agency with a longstanding reputation for doing some of the best work in the communications industry llidura Consumer is a public relations agency that combines pure-play A healthcare and lifestyle expertise to deliver fresh thinking for consumer healthcare, wellness and beauty clients B iosector 2 is a global healthcare public relations agency that partners with visionary clients to deliver groundbreaking programs that improve peoples lives randtectonics ID collaborates with clients to become agents of brand B change within their organizations, providing the tools, ideation, and creative execution to support any branding directive randtectonics Access is a specialist market access agency that designs, B facilitates and delivers tailored solutions to optimize patient access to our clients brands handler Chicco Productions creates experiential initiatives on behalf C of clients and sponsors that raise awareness of issues, explore problems and motivate people to make behavioral changes in their lives eterminus is a strategic research company focused on using research at D every level of the communications process from insights, to program development to evaluation ngenda Communications is a healthcare communications agency that I specializes in dimensionalizing target audiences and developing gender specific communication programs within the healthcare environment itmus is a medical marketing and education agency that offers innovative L approaches to opinion-leader development and mobilization, health economic modeling and communications, educational events and publications nition is a full-service design company with deep expertise in healthcare creative, advertising, interactive and production services erStone Digital is dedicated to establishing community-based digital V and social health innovations that will influence and, ultimately, change the way individuals, organizations, and governments approach and interact with healthcare

PRimeCut Spring 2010

2010 is off to a rapid start, stepping in where 2009 left off. The industry in 2009 was is constantly evolving, with policy changes on both sides of the Atlantic, mergers and acquisitions, and a renewed FDA presence in the United States, especially on social media guidance. This issue of PRimeCut takes a look at some of the topics and trends we think will rise to the top over the next 12 months. As youll see, theres a lot for the industry to tackle in the coming months, which means there is plenty for communications specialists to tackle as well. Helping industry through the year ahead will require foresight, expertise and insider knowledge of a complex, dynamic and evolving landscape. Though this issue is about looking ahead, we cant help but reflect on the past month here at Chandler Chicco Companies: a month in which we were named The Holmes Reports Healthcare Agency of the Decade and The Holmes Reports EU Healthcare Agency of the Year. One Holmes write-up noted that our industry knowledge, strategic insight, and breadth of services puts CCC in a position to help clients navigate [the] challenging landscape. And, just in the past few weeks, Chandler Chicco Companies was named one of The Sunday Times Top 100 Best Small Companies to Work for in the UK. We are so very proud of and humbled by these honors and after 15 years, we do not take anything for granted. It is clients and partners like you who make what we do so rewarding. We look forward to having you with us as we forge ahead in 2010.

1. Dont Say No Say Yes, but
At the beginning of 2009, following his inauguration, President Obama was at the height of his political power. While facing multiple inherited challengesmost notably a global economic crisis and wars in both Iraq and Afghanistanthe President, nonetheless, set ambitious health reform in motion. In those heady days, the White House and congressional leaders were suggesting health reform would be done and signed into law by mid-summer and the message sent by the White House to interest groups across the nation was get on board or get run over. More than a year later, it appears that those who found a way to help, usually setting conditions for their support, fared better than those who just said no. Hospitals, big pharma and doctors met with Senate leadership and the White House and quickly made deals. The Obama Administration wanted the support of these groups in order to help ensure the success of reform. But, health reform would have to be paid for, in part, by cuts in Medicare payments to hospitals and drug companies. Rather than oppose reform outright, hospital leaders and PhRMA decided to set conditions on their support. Most observers agree that hospitals and drug companies made a good bargain, and their support for reform prevented much larger cuts from being imposed. Sim ilarly, doctors set the conditions for their support. In exchange for the elimination of the scheduled 21% reduction in physician pay set for this year, along with other policy changes, doctors switched from opposing the reform effort to supporting it.
2. Message Discipline Matters
Among the reasons for the success of the Obama campaign was that they stuck to their message. The campaign was about CHANGE. Everything they said went through that lens. It was simple, understandable and enormously effective. The same clarity and consistency of message has not been true of the Obama White House in their handling of health reform. Since the outset, the White House has said health reform has been about: M aking sure all Americans have health insurance and the bills will probably do a pretty good job of making that happen. But polling has shown that while everyone thinks this is a good idea, those who have insurance do not want to pay more or get less to cover everyone else. Rather than sell Americans on why everyone would benefit from covering everyone, they shifted messaging to Reducing the costs of healthcare however, the bills do very little to actually reduce overall costs of care and could, according to some economists, accelerate the rate of healthcare inflation once everyone is covered. So, the message became topping insurers from hurting us S while making so much money and the bills do some of this. But it is not clear that Americans trust government any more than they trust insurance companies and, in fact, most Americans who have insurance are pretty happy with their plans.

It appears that those who found a way to help, usually setting conditions for their support, fared better than those who just said no.
Insurers pursued a different strategy, choosing not to make a deal. They continue to work against reform, both directly through their own efforts and by supporting campaigns led by the U.S. Chamber of Commerce and others. While it is not clear that a deal could have been made with Americas Health Insurance Plans (AHIP), the industrys lobbying arm in Washington, the White House continues to portray insurers as the root of all evil in healthcare. Perhaps the insurers tried to make a deal. Or perhaps the White House believed they needed an enemy and insurers were their best target. Regardless, those groups that found a path to supporting some kind of reform are better positioned for the months ahead.
With constantly shifting messages, health reform supporters had trouble staying on message, delivering the same talking points and arguments to persuade the American public over time. And that has made it much easier for reform opponentswhose message is simply noto succeed. Part of the difficulty in achieving clarity of messages was the inability of the Democrats and the Obama Administration to settle on what they hoped to accomplish with health reform. This absence of agreement led to the infamous town-hall eruptions during the August congressional recess. At that time, there were three bills in the House and two in the Senate. All were very different. Most point to that four-week period as the moment the public began to turn against reform. Those opposed to health reform were passionate and their message was clear. Those in favor of reform could not explain what Congress was doing or why they were in favor of the complex changes Congress was
making. How would the bills work? What would the proposals mean for those who already have insurance? What will it cost me? The key takeaway from last summer? Politics abhors a vacuum, and if you cannot define the policy change you seek, your opponents will.
sights; and state governers, many whom must face the voters in 2010, are seeking help from the Administration to close Medicaid funding gaps, as Medicaid spending increased significantly during the recession.
3. In a close vote, everyone has leverage but dont be the last one in the tent
Weve seen the lengths to which Senate leaders have gone (or sunk) to secure each of the 60 votes needed to move health reform to the next stage. Much has been written about these deals. Weve seen the Louisiana Purchase to secure the support of Sen. Mary Landreiu (D-LA); a perhaps not entirely legal subsidy for Nebraskas Medicaid programthe cornhusker kickbackin order to secure Sen. Ben Nelsons (D-NE) vote; and the death of the public plan to get Sen. Joe Lieberman (D-CT) on board. And there have been many more. In the House, it takes relatively few Democrats to change policy, as Rep. Bart Stupak (D-MI) and the Catholic Church demonstrated when they led the campaign to include strict anti-abortion language in the House-passed bill. While everyone has leverage, not everyone knows when to use it. On the one hand, biding your time and holding out until late in the process increases leverage to give you maximum advantage. On the other hand, being last can draw unwanted attention. The last Senator to commit, Ben Nelson, and his wife were shouted out of a restaurant recently by angry constituents upset that he provided the margin of victory for passage of health reform. He still has not committed to voting for final passage and may wish to make up his mind soon if he wants to enjoy his pizza in peace.

5. Americans do not trust government but theyre going to get more of itat least in healthcare
The mistrust is pretty clear. We wont attempt to explain the origins of it or why it continues, but our collective mistrust of government is growing, not shrinking. That much hasnt changed. Democrats in Congress will be working feverishly to rebuild some level of trust in government over the next several months, as there is a direct relationship between faith in government and voters views toward the incumbent, governing party. Despite the mistrust, the U.S. government is moving inexorably toward a growing and larger role in delivering American healthcare. edicare and Medicaid policies are driving morenot fewer M of the decisions by private payers; DA approval and enforcement are growing more rigorous, with F fewer new drug approvals, increasing requirements of postapproval trials, increasing use of REMS programs and a growing FDA and FTC mistrust of direct-to-consumer communications, including extreme wariness about social media; he implications of comparative effectiveness are far-reaching T and likely to drive coverage and, ultimately, business decisions by drug companies, hospitals, physicians, and, perhaps most importantly, public and private payers. nd while there will be no public plan this time in the reforms, A the public plan is still on the table and remains a priority for many Democrats. There is every reason to believe that single-payer advocates will be back, pointing to the inefficiencies and complications that will inevitably arise from the health reform morass that Congress is about to pass. It is a good time to review the lessons weve learned over the last 18 months. Chances are, well be applying what weve learned in the months ahead.
4. Politics drives policy
At the beginning, the objectives for health reform were clear: ensure access to health insurance for all Americans, reduce costs and end the so-called onerous practices of the insurance industry. Then some other objectives were added. Do it for less than $900 billion over ten years. And dont add a penny to the deficit. And try to keep your core supporters happy. And make it possible for moderate Democrats to support the bill and get re-elected. And, oh yes, dont raise taxes on the middle class. The result, of course, is a hash of compromises and deals cut to achieve the ultimate objectivepassage of health reformwhile meeting all of the other objectives that have emerged during the debate. These were not policy decisions, they were political choices. And there will be more politics to come. For example, we would expect to see a series of smaller reforms move forward, even if the big bill does not. Health insurers remain in Democrats
For information on Chandler Chicco Companies public affairs and policy capabilities, contact Al Jackson at ajackson@chandlerchiccocompanies.com.

whats your GQ?

gender intelligence in healthcare marketing

By Kelly Teasdale, CCCUK

Gender intelligence, the ability to accurately understand the impact that gender has on an individuals behaviour, is becoming increasingly important for healthcare marketing professionals.
Once a neglected subject area, gender is now at the forefront of strategic thinking in marketing, with a significant number of experts encouraging professionals across all disciplines to improve their gender quotient (GQ). The goal is to communicate more effectively, build brand loyalty and increase sales. In their book, Dont Think Pink, Lisa Johnson and Andrea Learned argue for gender intelligent marketing by demonstrating a critical need to breakdown old-fashioned stereotypes, assumptions and a one-size-fits-all approach to marketing to women that has been prevalent and yet ineffective over recent decades. They refer to this as the Pink Thinking Corporate Recipe, an approach to gender that relies on dated information, a resistance to new ideas and a deep rooted fear of turning men off consumer brands. Chryslers Dodge La Femme vehicle is a case in point. Despite a huge investment made in manufacturing a feminine car with Heather Rose exterior, upholstery and trim, complete with matching raincoat, umbrella, purse, lipstick and compact, the model failed to make a significant impact on the 20 million modern American women with a drivers license in the 1950s, and was pulled off the market just as quickly as it had appeared. And, if those traditional ideals of femininity were failing to reach target audience in the 1950s, it is difficult to imagine how they might resonate with women today. Over recent years, the societal and economic roles of both women and men have changed dramatically. Women have outpaced men in both education and earnings growth and according to a report recently published by the Pew Research Center, American men now stand to gain a substantial amount
more from marriageeconomically speakingthan women, a complete gender role reversal from 40 years ago. In addition to these remarkable changes in marriage economics over the last 40 years, we have also seen marriage rates fall, divorce rates rise, the significant growth of the single parent household and the emergence of a whole new familial figurethe Stay At Home Dad. Women now influence up to 80 percent of all purchasing decisions for households. They are also said to be the main caregivers for the family, the main influencers of who will go to the doctor and when they will go, and the main drivers of compliance to medications amongst both family and friends. As healthcare professionals, the influence of women is also significantly increasing. Almost all physician assistants and nurse practitioners, with their growing prescribing and primary care responsibilities, are now female and by 2025, it is said that women will represent almost half of all physicians. In order to effectively navigate these changing gender dynamics, improve their GQ and develop marketing programmes that reflect the needs of target audiences, healthcare marketing professionals need to embrace the substantial body of research completed by psychologists, neurologists, sociologists and market researchers on gender. Women hear things differently from men; they also relate to others and make decisions in an entirely different way. The only way to truly understand how marketing messages will be received by both women and men is by attaining an in-depth knowledge of their values, instincts, societal and familial roles.

Ingenda Communications is a healthcare marketing agency within the Chandler Chicco Companies network that specialises in gender-based communications. Our team invests the time and energ y needed to get to the heart of what makes our clients target audiences tick, both female and male, with the support of researchers, planners, strategists, gender theorists, proprietary tools and an integrated approach to communication disciplines. To discuss your GQ, contact Kelly Teasdale at KTeasdale@chandlerchiccocompanies.com.

Key Trends for 2010

Like every other sector, the healthcare industry found that the global recession of 2009 exacted a toll. But companies emerging from the difficult financial environment of last year may be better prepared in many ways to adapt to the new economic realities that lie ahead. The main challenges in 2010and some of the trends well be watchinginclude evolving business models, comparative effectiveness, biogenerics/biosimilars, follow-on biologics, global pricing pressures and, perhaps, healthcare reform. Each of these has specific implications for those in charge of corporate and marketing communications. Considered together, it is clear that the role of communications has never been more important nor required such breadth of knowledge and skill. In the second half of 2009, we saw investor confidence return full-force, helping generate a 50 percent increase in major stock market indices from their lows at the end of March 2009. Many analysts are predicting that U.S. and global capital markets will continue to strengthen in the months ahead, albeit not without fits and starts, since a great deal of the recovery has been driven by stimulus funding and
What They Mean to Healthcare Marketers
By Sydney Rubin, CCCUS low interest rates set by the Federal Reserve and finance ministers. Real, sustainable economic growth in the coming year remains uncertain. While it promises to be another challenging yearalthough less volatile than the lastwere all better positioned to face it. Heres what we see for the year ahead and the implications for communications in 2010. Pharmaceutical companies will continue to seek revenue growth to replace blockbusters going off patent. Smaller biotechs will continue to seek partnerships and M&As to secure the financing they cant find in tight capital markets. In 2010, both large pharmaceutical and large biotechnology companies will continue to compete for companies with advanced product pipelines as well as for companies with key technologies. This year, however, major medical device makers, healthcare IT companies and even generics companies will enter the competition to acquire technology. Companies that enjoy well-known, respected brands and excellent reputations will have an edge in the M&A race. The once clear lines separating pharma, biotech, devices, diagnostics, health IT, services, and generics/biosimilars

A variety of new regulatory issues will emerge as the pharmaceutical industry continues to evolve to a model that is somewhat closer to that of innovative biotech.
already have blurred and the convergence should accelerate this year as companies respond to new market opportunities that present themselves. Fueling the trend will be Americas shifting focus from sickness to wellness and from treatment to prevention. Companies that once needed only deep expertise in pharmaceutical marketing must now cultivate equally strong capabilities in biotech, diagnostic, device, technology and consumer products marketing. The global recession highlighted the new economic reality emerging markets, particularly in China, India and Brazil, are growing faster than the United States and Europe and will continue to do so. The United States will be defending its dominance in biotech as some other countries and regions position themselves for leadership in some technologies and business sectors. Reforms underway in China, for example, promise to boost the homegrown generics and biotech industries there. In these big three economies, as well as in other emerging marketsparticularly those of Latin Americaincreasing affluence, a growing middle class, and government policies will make healthcare big business. Cross-border integration, multi-cultural expertise, basic language skills, on-the-ground experience with legal and regulatory and global reach are all table stakes for communications teams wishing to compete in the years ahead. The next 12 months are sure to see additional industry consolidation and an operational shift within pharmaceutical companies from a vertically integrated model to something closer to virtual integration. Particularly in biotech, this year may prove that geography becomes less and less important as companies continue to develop more virtual (and cost-effective) business models and operate in orbits around diseases, markets or shared research. Communications teams, in some cases, already operating as virtual teams, could help facilitate this evolution and provide corporate counsel on operational effectiveness in a virtual environment. Regardless of what happens with healthcare reform in 2010 (see pages 4-6), the legacy of last years efforts will be a continuing shift from cost to value within the U.S. healthcare system. Employers, providers and governments will look to reduce costs by increasing efficiency and delivery,

while rewarding behaviors that promote healthy lifestyles. Medicare and Medicaid will expand their role in delivery and reimbursement and the likelihood of expanded negotiations will put increased pressure on pricing. The landscape in 2010 could look increasingly familiar to companies that have been negotiating prices in Europe for the last few years. All of this will be amplified by the severe budgetary shortfalls at the state level, and with the proposed freeze in federal spending announced by President Obama in his State of the Union Speech in January, there wont be any federal financial cavalry coming to the rescue of struggling states. All of this lends increased urgency to communications around disease states and products as companies must clearly define the benefits and importance of treatmentsall viewed through the new lens of value. Beyond sweeping reform and pricing, the regulatory environment in Washington DC also promises to be far more complex in 2010. Comparative effectiveness research has entered the equation and policymakers will look at cost/value + utilization/efficacy in setting policies and applying them. The comparatively high price of biologics and their increasing use will put pressure on Congress to open the door to allowing the FDA to approve generic versions of biosimilars. A variety of new regulatory issues will emerge as the pharmaceutical industry continues to evolve to a model that is somewhat closer to that of innovative biotech. Evolving intellectual property issues, regulation around stem cells used in development and questions posed by the scientific innovation driving advances in personalized medicine, all may raise challenging new regulatory and policy questions in the year ahead. Communications teams must stay on top of the issues and the ongoing debate, and work more closely than ever as partners with legal and regulatory to assure the company voice is heard, reputation is protected and brand is advanced. As the old Washington adage goes, If youre not at the table, youre on it. The year ahead, if nothing else, is sure to provide communications professionals with a full plate.
To learn how Chandler Chicco Companies can provide strategic healthcare communications counsel for you in 2010 and beyond, email contact@chandlerchiccocompanies.com.

The Year of the Patient

By Ritesh Patel, VerStone Digital

At no time in history have patients had more access to information about their health. Today patients live in a sociodigital world, where digital platforms intersect with online social communities. They can search for information, engage with fellow patients, contact disease state experts, consult third-party organizations, solicit health advocates, influence policy makers, as well as chat with friends and family. 2010 promises to be the year of the patient. The growth in user-generated content is extraordinary. According to Neilson, social media sites are the most popular destinations globally. In 2009, we ended with some impressive numbers: 1.72 billion Internet users 126 million blogs 1 billion videos on YouTube 4 billion photos shared on Flickr 400 million Facebook users Patients are redefining the sociodigital environment from search to consumption of hea lt h i n for m at ion. Ju xt apo s e d against the shrinking healthcare media landscape is an explosive increase in information to be found in blogs, chat rooms, message boards, social networks and health communities. to become the arbiters of accurate and reliable information for patients. But the regulatory environment is murky and there has been no clear direction from the FDA. However, industry is slowly adopting sociodigital strategies. Our recommendation is that the sociodigital medium is viewed as a channel to support overall corporate or brand communications strategies. There are three areas emerging where industry can help patients become better informed about their health: 1. Search Google and other search engines are the first place people look for information. Search engine optimization is critical in making credible and scientific content findable on the web. 2. Blogs Not only are many former healthcare journalists blogging and flourishing in this forum but so are a lot of patients and surprise! they are gaining thousands of readers, as they talk about living with a condition or caring for someone who is. These bloggers are excellent potential ambassadors (see sidebar). 3. Social Media There is no such thing as a Facebook strategy or a Twitter strategy. To engage in relevant social media, it needs to be part of an overall comprehensive communications strategy and not a standalone program. Sociodigital forums include but are not limited to:
102.3 million U.S. patients now go online to research prescription drugs and to learn how to manage their conditions.
About one in five consumers is now using online content and tools to compare prices of health or medical products. More than 80 million U.S. adults use social media for health-related issues, creating or using content on health blogs, message boards, chat rooms, and health social networks, as well as from health communities, and patient testimonials.

Patients are now leveraging sociodigital tools for health information just as the well-informed consumer did five acebook similar to TV, but with 400 F years ago when researching big ticket Cybercitizen Health by Manhattan Research million people purchases or travel arrangements. In fact, according to the Cybercitizen Study by Twitter akin to radio, great for outreach Manhattan Research, the e-Health consumer market has grown and short bursts of information to help guide patients to significantly in the past five years, from 90 million online relevant content consumers looking for health information in 2004 to nearly 160 ouTube this video portal is a great medium to Y million in 2009. educate visually And perhaps because health is such an intensely personal topic, patients are connecting deeply in online forums to band Ultimately, patients will continue to go online, seek, participate, together with like-minded people living with a disease, become and share health information within the sociodigital ecosystem. spokespeople via blogs, start smart Twitter streams, produce Industry will need to be there to join the conversation and be part of their sphere of influence. advocacy videos for disease states and much more. The patient is firmly in charge, becoming informed and using After all, in 2010, patients rule. sociodigital tools to understand their health and manage their life. This growth has also led to a lot of dubious online content. There is a need for healthcare and pharmaceutical industry leaders
To find out how Chandler Chicco Companies can help you make the most of social and digital strategies, contact Ritesh Patel at rpatel@chandlerchiccocompanies.com.

PRimeCut Spring 2010 11

Patient Blogger Engagement
In todays digital era, patient bloggers are citizen journalists with eyes and ears on the groundeverywhere. Meanwhile, the pool of pharmaceutical and healthcare journalists continues to shrink, providing entre for patient bloggers to fill the information gap left behind. It only makes sense as healthcare marketers to engage influential patient bloggers and benefit from their sphere of influence. However, while many are savvy with a deep understanding of their particular health topic, others, well lets just say that they may not always get the facts straight or understand the nuances of fair balances or labeling. In addition, patient bloggers are not bound by a code of ethics. The vast majority of journalists subscribe to an ethical code which states The duty of the journalist is to seek truth and provide a fair and comprehensive account of events and issues. Conscientious journalists from all media and specialties strive to serve the public with thoroughness and honesty. In our heavily regulated industry, its critically important that we carefully engage patient bloggers and help them to report with a journalists thoroughness and honesty. To do that, we have come up with the following seven points to guide you R-E-S-P-E-C-T. through patient blogger engagement.

By Trine Hindklev, CCCUS

Stay away from pay for play. Paying bloggers to post about your product or service may seem like a good idea, but in the heavily regulated health and pharmaceutical industry, its important to be unbiased. However, clearly defined advertising on blogs or engagement in other forms of transparent commercial interaction is acceptable.
Know thy bloggers. Just as when reaching out to a journalist, it is equally important to have a good handle on common themes, writing style, hot buttons, experience and tone.
Read, read, read. Its imperative to continuously monitor targeted bloggers. Unlike journalists, bloggers reports are biased by on their own experiences versus the more balanced approach by journalists. Their POV can change rapidly and very publicly.
Its important to respect a patient bloggers rights to report his or her opinion and to make honest statements regarding products. By all means, point out inaccurate comments and share correct information with the patient blogger for future reference, but aggressively challenging posts in an on-line forum and/or making demands for a retraction often backfires.
SWAG transparency. If you are sending samples to bloggers, its in your best interest to ask that it is disclosed in the bloggers post.
Educate. Serious patient bloggers will appreciate gentle guidance on how the FDA regulates pharmaceutical companies communications with consumers. Once you have established a relationship, offer educational information about reporting on-label, including the significance of fair balance when discussing a treatment on their blog.
Do not call list. Believe it or not, just like journalists, there are bloggers who just do not want to hear from us. Keep a list and honor it. They may come around at a later date. Real relationships are based on mutual value and respect.
Spotlight on Germany: A Leader in the Global Healthcare Market
By Dr. Irene Haas, Managing Director and Co-Founder, Haas and Health Partner Medical discoveries and breakthrough inventions made in Germany, from the synthesis of acetylsalicylic acid in 1897 to the identification of the human papilloma virus as a main cause of cervical cancer by Nobel Prize winner Professor Harald zu Hausen, have and will contribute strongly to the global effort of improving healthcare. German pharmaceutical companies such as Bayer Schering Pharma, Boehringer Ingelheim and Merck Serono, all rooted in a strong research tradition, are standing at the forefront of medical progress. Germanys healthcare market is a key driver not only in research but also in terms of business: it is the third largest healthcare market worldwide and only second to the United States in global biopharmaceutical production. As in other pharmaceutical markets around the world, the changes Germany has seen lately are radical. The call for cost cutting is transforming a traditionally doctororiented, sales forcedominated marketplace with rigid but predictable structures, into one that is becoming increasingly fractionated by contracts between companies and payers, and payers and physicians, with the patients potentially losing quality care (innovations) and free choice of doctor. In terms of marketing communications, these changes need in-depth understanding, anticipation and innovative approaches. Haas & Health Partner, as well as SanCom Communication Solutions, both members of Chandler Chicco Companies and among the top five healthcare communications agencies in Germany, pride themselves on proven track records of successfully helping their clients to achieve their goals among them, unparalleled product launches such as Yentreve, Concerta, Xigris, Efient, Vistabel, and Pradaxa. In connection with Chandler Chicco Companies, Haas & Health Partner has launched a new business unit, Brandtectonics Access Germany, that designs, facilitates and delivers tailored solutions to optimise patient access to clients brands. We are already successfully cooperating with the London operations of Brandtectonics Access on a project for GSK. With our shared experience and perspective, we will continue to strengthen and expand CCCs unique offering and capabilities for clients in Europes largest healthcare market.

To find out more about Haas & Health Partner, contact Dr. Irene Haas at haas@haas-health.de. To find out more about Chandler Chicco Companies Global Healthcare Network, please contact Fiona Hall at fhall@chandlerchiccocompanies.com.
Daiichi Sankyo & Lilly: Launching the New Oral Anti-platelet Agent Efient in Germany
In 2008, Daiichi Sankyo Germany and Lilly Germany chose Haas & Health Partner as their PR partner to support prelaunch, launch and postlaunch communication for their new oral anti-platelet agent prasugrel [Efient in the EU, Effient in the US] in the German market. The main goal was to create awareness for prasugrel/ Efient as the new treatment option to prevent atherothrombic events in ACS patients undergoing PCI by ensuring continuous, robust and positive media coverage. Focusing on data and product milestones, the PR team highlighted the unmet medical need and consequences of uncontrolled ACS. Subsequently, prasugrel was established as an alternative to current oral anti-platelet therapies in medical trade media. To build and win the desired media share of voice in the area of ACS treatment and cardiology, it was crucial to leverage the launch of Efient to maintain awareness/media coverage throughout the year, which required a unique event to spark attention. The Major Cardiac [PR] Event took place at the MACE restaurant in Munichs city center in May 2009. The multi-sensory Efient Media Launch Experience created the atmosphere of a medical congress with poster presentations, data review sessions, panel discussions and hands-on training for the attending journalists, allowing them to perform a stent implantation on their own. Results: >> edia attendance: 17 journalists from all key M trade media outlets, including all lead titles in cardiology and general medicine >> edia coverage by the end of 2009: 18 trade media M clips [~1.1 million media impressions] >> he launch was covered throughout the year, T with journalists continuing to talk about their personal PCI experience
Chandler Chicco Companies

 

Tags

Controller Gigaset A345 Suunto T4 Maker W-865R 2002-11 NN-A554wbbpq Coolpix 7900 IC-M87 NV-GS320 TX-21MD3 CT-32G23W Janome MB-4 ZB2813 Psaf5 Player N200 KX-TG1100SP MFC-6490CW 25PT4523 C-500 Alcatel-lucent 4038 DV-18S-A PSC 2550 Behringer MS40 SHR-2160P250 LAC-M6600 PS50C687 BX2240 VPC-CA9 LE32R71B SC-HT850 B1100 Motorola V551 Workstation NAD 510 Cect I32 Focus-2006 2333TN Nikon 995 KX-FC228FX 10329 PSR-190 NVE-N055PV ERB34001W8 2730C LE37A551 TM-U220 750C Plus 42PQ2000 ZRT328W HL-5040 EL-520W Hipath 3500 Eo-ettl II Urei 525 DSC-W220 B Logic DM10 KDC-MP532U VGN-NR11s-S KX-FP81 WS-7016U IC-V210T 1100D 830 Trio SF-565PR XST AL2023W DT-50PY10 ED 220 KX-TC1740B Mitsubishi XL1U A1250 1100P Stopwatch S056 SM-5000 F35100ST Jackhammer IN 1 GSX-F 750 21FE3RGE-TY Receiver LN40A330 US2-PH61159 Provocal MV500I CDX-M30 HQ8240 17 Dect 521 HD9120 SE-U55 A-X77 Rcs-77h Paperport 11 CMT-C5 Gigaset C150 DES-3010GA R-202 ER3261BNS SPH-W4100 DCB-H360R Review Plus 12

 

manuel d'instructions, Guide de l'utilisateur | Manual de instrucciones, Instrucciones de uso | Bedienungsanleitung, Bedienungsanleitung | Manual de Instruções, guia do usuário | инструкция | návod na použitie, Užívateľská príručka, návod k použití | bruksanvisningen | instrukcja, podręcznik użytkownika | kullanım kılavuzu, Kullanım | kézikönyv, használati útmutató | manuale di istruzioni, istruzioni d'uso | handleiding, gebruikershandleiding

 

Sitemap

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101